Who owns Summit Therapeutics Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of SMMT from SEC Form 13F filings across 244 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 244 institutions disclosed 135.9M shares of Summit Therapeutics Inc. worth $1.98B — about 17.5% of shares outstanding; the largest disclosed holder is BAKER BROS. ADVISORS LP. Source: SEC Form 13F filings, parsed by EvidInvest.
244
13F holders
$1.98B
value, 2026 filers
17.5%
of shares outstanding (135.9M sh)
56
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of SMMT's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 32.8M | $477.7M | 2.4% | 4.2% | -9.9% |
| 2 | FMR LLC | 10.0M | $146.3M | 0.0% | 1.3% | -7.5% |
| 3 | STATE STREET CORP | 9.5M | $139.0M | 0.0% | 1.2% | +35.7% |
| 4 | BlackRock, Inc. | 9.5M | $138.8M | 0.0% | 1.2% | -1.3% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 5.7M | $83.6M | 0.0% | 0.7% | +0.4% |
| 6 | UBS Group AG | 5.2M | $76.3M | 0.0% | 0.7% | +42.2% |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5.0M | $73.5M | 0.0% | 0.6% | -3.7% |
| 8 | GOLDMAN SACHS GROUP INC | 4.5M | $65.8M | 0.0% | 0.6% | +1352.5% |
| 9 | PRICE T ROWE ASSOCIATES INC /MD/ | 3.9M | $56.7M | 0.0% | 0.5% | -53.0% |
| 10 | Point72 Asset Management, L.P. | 3.7M | $53.9M | 0.1% | 0.5% | +371.5% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 3.4M | $50.0M | 0.0% | 0.4% | +3.4% |
| 12 | MILLENNIUM MANAGEMENT LLC | 2.3M | $34.2M | 0.0% | 0.3% | +1760.3% |
| 13 | ADAGE CAPITAL PARTNERS GP, L.L.C.NEW | 2.0M | $29.0M | 0.0% | 0.3% | new |
| 14 | Balyasny Asset Management L.P. | 1.9M | $27.7M | 0.0% | 0.2% | +247.3% |
| 15 | CITADEL ADVISORS LLC | 1.7M | $25.1M | 0.0% | 0.2% | +290.7% |
| 16 | Aberdeen Group plc | 1.7M | $24.7M | 0.0% | 0.2% | +154.5% |
| 17 | Squarepoint Ops LLC | 1.6M | $23.2M | 0.0% | 0.2% | +159.1% |
| 18 | MORGAN STANLEY | 1.5M | $21.1M | 0.0% | 0.2% | -12.2% |
| 19 | NORGES BANKNEW | 1.4M | $20.1M | 0.0% | 0.2% | new |
| 20 | Logos Global Management LPNEW | 1.4M | $19.7M | 0.8% | 0.2% | new |
| 21 | Octagon Capital Advisors LPNEW | 1.3M | $18.2M | 1.6% | 0.2% | new |
| 22 | D. E. Shaw & Co., Inc. | 1.2M | $18.1M | 0.0% | 0.2% | -44.5% |
| 23 | Kynam Capital Management, LPNEW | 1.2M | $17.5M | 1.0% | 0.2% | new |
| 24 | Pictet Asset Management Holding SA | 1.1M | $16.4M | 0.0% | 0.1% | -14.3% |
| 25 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 976,851 | $14.2M | 0.0% | 0.1% | +1.7% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.